Lyophilization and Excipients: What Is Actually in the Cake
Search for peptide freeze-drying and the material returns a confident, well-established story: trehalose vitrifies, mannitol builds the cake, residual moisture is the critical quality attribute, and a properly formulated lyophile is stable for years. Every element of that story is supported by real work. Almost none of it describes what is inside a research peptide vial.
The gap is simple enough to state and rarely stated. That literature is about formulations — protein drug products deliberately built around excipients chosen to protect them. A synthetic research peptide is generally not a formulation. It is the dried residue of a purification step: material collected from preparative reversed-phase chromatography and freeze-dried directly from the eluent, with no stabilizer added because none was ever part of the design.
Understanding which protective mechanisms are present and which are absent is the whole question, and no certificate of analysis on the market answers it.
This article describes laboratory materials and in vitro systems. It is not a procedure.
What freeze-drying is actually doing
Lyophilization removes water in two distinct stages after freezing. Primary drying sublimes ice directly to vapor under vacuum, at a shelf temperature held below the formulation’s collapse temperature. Secondary drying then desorbs the water that remains bound to the solid, at higher shelf temperature and for longer than most people expect.
The freezing step is not a neutral prelude. Searles, Carpenter and Randolph demonstrated that a deliberate annealing hold above the glass transition temperature of the maximally freeze-concentrated solute, Tg′, alters ice crystal structure enough to change the primary drying rate and reduce vial-to-vial heterogeneity introduced during freezing. How the material was frozen is recorded in how it dries — and, downstream, in how uniform a batch is.
None of that appears on a certificate. Certificates report the endpoint, not the path.
Why excipients exist, and what happens when they crystallize
The protective mechanism that makes a good lyophile good is glassy immobilization. A sugar that remains amorphous forms a rigid glass around the solute, restricting molecular mobility so that degradation reactions requiring motion cannot proceed at a meaningful rate. Carpenter and Crowe’s infrared work on the interactions of carbohydrates with dried proteins is one of the foundational studies in this area, and the design principles were consolidated by Carpenter, Pikal, Chang and Randolph in 1997 into the reference framework still used for formulation work today.
The critical qualifier is amorphous. Izutsu, Yoshioka and Terao showed this directly, working with β-galactosidase and using mannitol and inositol as stabilizers. Additives in the amorphous state produced concentration-dependent protection of the enzyme. Crystallization during processing sharply reduced that protection, and a heat treatment applied before freeze-drying — which promotes crystallization — did the same. An excipient that crystallizes has stopped being a stabilizer while remaining fully present in the vial and fully invisible to a purity assay.
Recent work makes the same point with modern analytics. Gao, Ouyang, Hu and Fang freeze-dried insulin and glucagon in a matrix of formulations and stored them at 40 °C and 50 °C for up to three months. X-ray powder diffraction detected mannitol crystallization, including mannitol hemihydrate, and no detectable glass transition in mannitol-containing formulations — the signature of complete crystallization. The stability consequence followed: mannitol-containing formulations showed a significant decrease in purity and recovery by RP-HPLC over storage, with an increase in subvisible particles under stress, while trehalose-containing formulations preserved both physical and chemical stability by forming an amorphous glassy matrix that restricted molecular mobility.
Two conclusions follow, and the second is the one that matters here. First, excipient choice is not cosmetic; a bulking agent that crystallizes can be actively worse than nothing. Second — all of this describes vials that contain excipients.
What a research peptide cake usually is instead
Erckes and colleagues describe the ordinary production path plainly. Trifluoroacetic acid is the standard ion-pairing reagent in preparative reversed-phase purification of synthetic peptides, and lyophilization of the collected peptide-containing fractions produces a peptide–TFA salt. In their material the trifluoroacetate load was 0.333 ± 0.008 mg per mg of peptide salt, close to the ~25% w/w predicted stoichiometrically.
So the white cake in a research vial is typically the peptide, its counterion, and residual water. No sugar. No glass former. No bulking agent whose polymorphism anyone has characterized.
This has an underrated consequence for how the published stability data should be read. Almost every favorable long-term figure in the lyoprotectant literature was generated in a formulation with a stabilizer present and amorphous. Applying those numbers to an excipient-free peptide salt is not conservative extrapolation — it is quoting an experiment that was not run.
Residual water is the variable that does not stop moving
What an excipient-free cake does retain is water, and water is the mechanism that connects freeze-drying to shelf stability.
Strickley and Anderson quantified this for lyophilized insulin powders. Degradation rate in the solid state increased with water content at hydration levels well below the suspected glass transition, and approached solution-phase rates as water reached the 20–50% range that induces a glass transition. Their conclusion was that solid-state decomposition here is a water-induced reaction accelerated by the plasticizing effect of sorbed water. Costantino, Langer and Klibanov had earlier characterized moisture-induced aggregation of lyophilized insulin along the same lines.
Strickley and Anderson’s second finding is the one that ties this article to the vial in front of you. Solid-state pH–rate profiles ran parallel to the solution pH–rate profile, with an apparent pKa of about 4 independent of water content. The pH of the solution that was frozen is retained by the solid. For a peptide lyophilized out of an acidic TFA-containing eluent, the cake carries that acidity, and the degradation chemistry available to it was selected upstream in a purification laboratory.
Water content is measurable — Karl Fischer titration is the compendial method, and it is neither slow nor expensive. It is simply not on most certificates, including ours.
What our certificates say, and what they do not
Being specific is more useful than being reassuring. The KPV certificate — report DBAV-KPV-10-062226, lot 5814, tested 4 July 2026 by Testides — reports expected mass 10.00 mg, content mass 9.57 mg, fill accuracy 95.7%, purity 98.70% by HPLC-UV at 214 nm, and appearance “White Lyophilized Powder.” The Tirzepatide certificate, DBAV-TIRZ-10-052926, lot 5966, reports 10.90 mg against an expected 10.00 mg — 109.0% fill accuracy — at 99.88% purity, with the same appearance line.
Across the certificates published on this site, fill accuracy now spans roughly −4.3% to +9.0%. That range is ordinary manufacturing practice and it is disclosed lot by lot, which is the point of publishing them.
What no certificate in that set contains is a water determination, a counterion figure, a formulation or excipient statement, a cake appearance grade beyond the one-line description, or any retest date or expiry. The phrase “White Lyophilized Powder” is an appearance observation. It is not a statement about what else is in the cake, because nothing on the document is.
That is not a criticism of the laboratory. It is the honest scope of an HPLC-UV purity-and-content certificate, and the useful thing a supplier can do is say so rather than let the reader infer a formulation science that was never performed.
Where sourcing actually helps
Nothing about a certificate changes solid-state chemistry, but two sourcing variables do.
Time and temperature in transit act on a lyophilized cake through exactly the mechanism above — sorbed water and thermal exposure. Maple Research Labs holds inventory domestically and ships same-day from Santa Barbara, California, operating as a US-registered entity in Wyoming. A domestic shipment reaching a US laboratory in days, rather than an international parcel sitting in customs under uncontrolled conditions, is a genuine reduction in accumulated stress on the solid — and it is one of the few stability variables a purchasing decision can move at all.
The second is documentary. A lot-specific certificate from a named third-party laboratory, published openly, with its scope stated rather than implied, lets a laboratory decide what still has to be measured in-house. Water content, on an excipient-free cake, is usually first on that list.
For a certificate on a compound where fill accuracy and lyophilized appearance are both published lot by lot, see our Tirzepatide 10 mg listing.
Research use only. All materials described here are supplied for laboratory research purposes only. They are not drugs and are not intended for human use, human consumption, diagnostic use, or veterinary use. Nothing above is a procedure.
References
- Searles JA, Carpenter JF, Randolph TW. Annealing to optimize the primary drying rate, reduce freezing-induced drying rate heterogeneity, and determine Tg′ in pharmaceutical lyophilization. Journal of Pharmaceutical Sciences, 2001;90(7):872–887. DOI 10.1002/jps.1040. PMID 11458336.
- Carpenter JF, Crowe JH. An infrared spectroscopic study of the interactions of carbohydrates with dried proteins. Biochemistry, 1989;28(9):3916–3922. DOI 10.1021/bi00435a044. PMID 2526652.
- Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations — some practical advice. Pharmaceutical Research, 1997;14(8):969–975. DOI 10.1023/A:1012180707283. PMID 9279875.
- Izutsu K, Yoshioka S, Terao T. Decreased protein-stabilizing effects of cryoprotectants due to crystallization. Pharmaceutical Research, 1993;10(8):1232–1237. DOI 10.1023/A:1018988823116. PMID 8415413.
- Gao H, Ouyang J, Hu Z-B, Fang W-J. Pharmaceutics, 2025;17(12):1543. DOI 10.3390/pharmaceutics17121543 — freeze-dried insulin and glucagon, mannitol crystallization and stability at 40 °C and 50 °C.
- Erckes V, Streuli A, Chamera Rendueles L, Krämer SD, Steuer C. Towards a consensus for the analysis and exchange of TFA as a counterion in synthetic peptides and its influence on membrane permeation. Pharmaceuticals, 2025;18(8):1163. DOI 10.3390/ph18081163.
- Strickley RG, Anderson BD. Solid-state stability of human insulin I — mechanism and the effect of water on the kinetics of degradation in lyophiles from pH 2–5 solutions. Pharmaceutical Research, 1996;13(8):1142–1153. DOI 10.1023/A:1016043715791.
- Costantino HR, Langer R, Klibanov AM. Moisture-induced aggregation of lyophilized insulin. Pharmaceutical Research, 1994;11(1):21–29. PMID 8140052.
- Maple Research Labs. Certificates of analysis — KPV 10 mg, report DBAV-KPV-10-062226, lot 5814; Tirzepatide 10 mg, report DBAV-TIRZ-10-052926, lot 5966. Testides.